Table 2.
mtDNA copy number and risk of lung cancer across ATBC, PLCO, and SWHS studies by sex and smoking status
| ATBC (Ca 227/ Co 227)
|
PLCO (Ca 426/Co 436)
|
SWHS (Ca 221/Co 222)
|
Pooled |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mtDNA% | Ca/Co | OR* | 95% CI | Ca/Co | OR* | 95% CI | Ca/Co | OR* | 95% CI | Ca/Co | OR* | 95% CI |
| Overall | ||||||||||||
| Q1 | 52/57 | 1.00 | (ref) | 117/107 | 1 | (ref) | 54/56 | 1.00 | (ref) | 223/220 | 1.00 | (ref) |
| Q2 | 59/56 | 1.34 | (0.71–2.37) | 119/110 | 0.98 | (0.64–1.50) | 72/58 | 1.27 | (0.48–1.47) | 250/224 | 1.08 | (0.82–1.42) |
| Q3 | 43/57 | 1.15 | (0.61–2.17) | 96/108 | 0.84 | (0.55–1.29) | 44/53 | 0.84 | (0.48–1.47) | 183/218 | 0.83 | (0.62–1.11) |
| Q4 | 73/57 | 2.38 | (1.12–5.06) | 94/111 | 0.98 | (0.63–1.52) | 51/55 | 0.91 | (0.53–1.57) | 218/223 | 1.04 | (0.79–1.39) |
| P-trend | 0.049 | P-trend | 0.74 | P-trend | 0.42 | P-trend | 0.78 | |||||
| Female | ||||||||||||
| Q1 | - | - | 32/40 | 1 | (ref) | 54/56 | 1.00 | (ref) | 86/96 | 1.00 | (ref) | |
| Q2 | - | - | 38/41 | 1.51 | (0.74–3.11) | 72/58 | 1.27 | (0.48–1.47) | 110/99 | 1.34 | (0.89–2.02) | |
| Q3 | - | - | 41/44 | 1.47 | (0.73–2.98) | 44/53 | 0.84 | (0.48–1.47) | 85/97 | 1.03 | (0.67–1.58) | |
| Q4 | - | - | 56/44 | 2.12 | (1.07–4.22) | 51/55 | 0.91 | (0.53–1.57) | 107/99 | 1.24 | (0.82–1.89) | |
| P-trend | 0.043 | P-trend | 0.42 | P-trend | 0.59 | |||||||
| Male | ||||||||||||
| Q1 | 52/57 | 1.00 | (ref) | 85/67 | 1 | (ref) | - | - | 137/125 | 1.00 | (ref) | |
| Q2 | 59/56 | 1.34 | (0.71–2.37) | 81/69 | 0.76 | (0.44–1.28) | - | - | 140/125 | 0.89 | (0.61–1.29) | |
| Q3 | 43/57 | 1.15 | (0.61–2.17) | 55/64 | 0.59 | (0.34–1.05) | - | - | 98/121 | 0.69 | (0.46–1.02) | |
| Q4 | 73/57 | 2.38 | (1.12–5.06) | 38/67 | 0.55 | (0.29–0.99) | - | - | 111/124 | 0.92 | (0.62–1.35) | |
| P-trend | 0.049 | P-trend | 0.028 | P-trend | 0.39 | |||||||
| Never Smoker | ||||||||||||
| Q1 | - | - | 9/51 | 1 | (ref) | 52/53 | 1.00 | (ref) | 61/104 | 1.00 | (ref) | |
| Q2 | - | - | 11/51 | 1.35 | (0.49–3.72) | 66/58 | 1.15 | (0.68–1.94) | 77/109 | 1.17 | (0.74–1.85) | |
| Q3 | - | - | 12/42 | 1.23 | (0.43–3.57) | 40/51 | 0.79 | (0.44–1.40) | 51/93 | 0.86 | (0.52–1.41) | |
| Q4 | - | - | 14/54 | 1.49 | (0.55–4.08) | 46/49 | 0.94 | (0.54–1.65) | 60/103 | 1.03 | (0.64–1.68) | |
| P-trend | 0.49 | P-trend | 0.54 | P-trend | 0.79 | |||||||
| Ever Smoker | ||||||||||||
| Q1 | 52/57 | 1.00 | (ref) | 108/56 | 1 | (ref) | 2/3 | 1.00 | (ref) | 162/116 | 1.00 | (ref) |
| Q2 | 59/56 | 1.34 | (0.71–2.37) | 108/59 | 0.91 | (0.56–1.47) | 6/0 | - | - | 173/115 | 1.03 | (0.73–1.47) |
| Q3 | 43/57 | 1.15 | (0.61–2.17) | 84/66 | 0.72 | (0.44–1.17) | 4/2 | 4.33 | (0.24–79.49) | 132/125 | 0.78 | (0.54–1.12) |
| Q4 | 73/57 | 2.38 | (1.12–5.06) | 80/57 | 0.84 | (0.50–1.39) | 5/6 | 1.05 | (0.087–12.81) | 158/120 | 1.05 | (0.73–1.49) |
| P-trend | 0.049 | P-trend | 0.33 | P-trend | 0.46 | P-trend | 0.81 | |||||
| Male Smoker | ||||||||||||
| Q1 | 52/57 | 1.00 | (ref) | 78/38 | 1 | (ref) | - | - | 130/95 | 1 | (ref) | |
| Q2 | 59/56 | 1.34 | (0.71–2.37) | 78/40 | 0.8 | (0.45–1.45) | - | - | 137/96 | 0.94 | (0.63–1.39) | |
| Q3 | 43/57 | 1.15 | (0.61–2.17) | 53/45 | 0.58 | (0.32–1.06) | - | - | 96/102 | 0.69 | (0.46–1.03) | |
| Q4 | 73/57 | 2.38 | (1.12–5.06) | 33/37 | 0.50 | (0.25–0.98) | - | - | 106/94 | 0.95 | (0.63–1.43) | |
| P-trend | 0.049 | P-trend | 0.021 | P-trend | 0.45 | |||||||
Alpha-Tocopherol Beta-Carotene (ATBC), Prostate, Lung, Colorectal, Ovarian (PLCO), Shanghai Women’s Health Study (SWHS), Cases (Ca), Controls (Co), Odds Ratio (OR), 95% Confidence Interval (95% CI), Quartile (Q1–Q4), Median (M1, M2)
%Quartiles: ATBC: <100.6, ≥100.6–124.8, ≥124.8–151.5, ≥151.5; PLCO: <90, ≥90–114, ≥114–145, ≥145; SWHS: <93, ≥93–124, ≥124–162, ≥162; Median: ATBC: ≤124.8; PLCO: ≤114, SWHS: <124
*
Adjusted for age, BMI, pack-years, race, sex, date of enrollment, center (if applicable), study